REBECCA: Key Study Results
Median OS was 5.6 months (interquartile range [IQR], 2.4–11.4)
12-month OS rate was 22 % and 12-month PFS rate was 7 %
Identified prognostic groups of patients with low, intermediate, and high risk of death,
with a
median survival of 9.2, 5.2, and 2.5 months
The low-risk group (regorafenib high OS benefit) with a maximum prognostic score of
3, represented 34 % of patients having a median OS of 9.2 months
The occurrence of HFSR within the first month of treatment was related to a better
OS
Identified several variables independently associated with poor OS:
High ECOG PS (≥ 1)
A shorter time from initial diagnosis of metastases
Initial REG dose <160 mg
>3 metastatic sites
Liver metastases
KRAS mutations
